Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference

Rhea-AI Summary

Allena Pharmaceuticals (NASDAQ: ALNA) announced that Dr. Louis Brenner, CEO, will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 13, 2021, from 5:00 to 5:25 pm ET. The company will also hold one-on-one meetings on July 13-14, 2021. Allena is focused on developing oral enzyme therapeutics for rare metabolic and kidney disorders, with its lead candidate, reloxaliase, currently in a Phase 3 clinical trial for enteric hyperoxaluria. A replay of the webcast will be available on Allena's website for 90 days.

NEWTON, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference. Management will also be available for 1x1 meetings on July 13-14, 2021. Details for the presentation are below:

Ladenburg Thalmann Healthcare Conference Presentation
Date:	Tuesday, July 13, 2021
Time:	5:00 – 5:25 pm ET
Track:	2
Webcast Link:	https://wsw.com/webcast/ladenburg7/alna/2382292

A replay of the webcast will also be available on Allena’s website for approximately 90 days under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com.

About Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study currently in progress and a Phase 2a program planned for the second half of 2021.

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel: 617-430-7577
arr@lifesciadvisors.com

FAQ

What is the date of Allena Pharmaceuticals' presentation at the Ladenburg Thalmann Conference?

The presentation will take place on July 13, 2021.

What time will Dr. Louis Brenner present at the conference?

Dr. Louis Brenner will present from 5:00 to 5:25 pm ET.

Where can I watch the Allena Pharmaceuticals presentation?

You can watch the presentation at the following link: https://wsw.com/webcast/ladenburg7/alna/2382292.

What is the focus of Allena Pharmaceuticals?

Allena Pharmaceuticals focuses on developing first-in-class oral enzyme therapeutics for rare metabolic and kidney disorders.

What is the status of Allena's lead product candidate, reloxaliase?

Reloxaliase is currently being evaluated in a pivotal Phase 3 clinical program for enteric hyperoxaluria.

Will there be a replay of the Allena Pharmaceuticals presentation available?

Yes, a replay will be available on Allena's website for approximately 90 days under 'Events and Presentations'.